BP Boost May Limit Use of Glucagon Receptor Antagonist in T2DM

This article originally appeared here.
Share this content:
Statistically significant increases in BP, MAP, and serum lipid levels were observed with LY2409021 treatment at a dose that lowered HbA1c and glucose levels.
Statistically significant increases in BP, MAP, and serum lipid levels were observed with LY2409021 treatment at a dose that lowered HbA1c and glucose levels.

(HealthDay News) — For patients with type 2 diabetes, once-daily treatment with the glucagon receptor antagonist LY2409021 is associated with increases in ambulatory blood pressure (BP), according to a study published online in Diabetes, Obesity and Metabolism.

Christof M Kazda, MD, PhD, from Eli Lilly and Company in Neuilly-sur-Seine, France, and colleagues conducted a 6-week randomized trial to examine the effects of once-daily administration of LY2409021 versus placebo on systolic blood pressure (SBP), diastolic BP (DBP), and mean arterial pressure (MAP) using 24-hour ambulatory BP monitoring. Participants included 270 patients with type 2 diabetes treated with diet/exercise ± metformin.

The researchers found that 24-hour mean SBP was increased after 6 weeks of LY2409021 treatment, with a least squares mean (LSM) difference of 2.26 mm Hg versus placebo (95% confidence interval [CI], 1.11 to 3.40; P < 0.001). There were also increases in 24-hour mean DBP and MAP, with LSM differences of 1.37 mm Hg and 1.67 mm Hg, respectively, vs placebo (95% CIs, 0.66 to 2.08 and 0.86 to 2.47, respectively; both P < 0.001). LY2409021 treatment correlated with reduced hemoglobin A1c (HbA1c) levels at week 6, with a LSM difference of −0.49% vs placebo (95% CI, −0.56% to −0.42%; P <.001). LY2409021 treatment correlated with small but significant changes in serum lipid and aminotransferase levels (all P <.05 vs placebo).

"Statistically significant increases in BP, MAP, and serum lipid levels were observed with LY2409021 treatment at a dose that lowered HbA1c and glucose levels," the authors write. "These effects may limit the clinical utility of LY2409021."

Several authors disclosed financial ties to Eli Lilly, which developed LY2409021 and funded the study.

Reference

  1. Kazda CM, Frias J, Foga I, et al. Treatment with the Glucagon Receptor Antagonist LY2409021 Increases Ambulatory Blood Pressure in Patients with Type 2 Diabetes. Diabetes Obes Metab. 13 February 2017. doi: 10.1111/dom.12904

Related Slideshows

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup